What Is the Treatment of Hyperchylomicronaemia? First-Line Management
Clinical Scenario
Hyperchylomicronaemia is characterised by severely elevated triglycerides driven by chylomicron accumulation. Without effective management, patients face substantial risk of acute pancreatitis and significant impairment of quality of life.
Treatment Approach
First-line management centres on a strict dietary modification strategy — specifically a very-low-fat approach — combined with attention to lifestyle factors and certain substances or medications that may worsen triglyceride levels, while ensuring nutritional adequacy is maintained.
The full structured protocol details the specific dietary parameters, supplementation requirements, and exclusions. Access the complete regimen below.
Treatment Goals
The clinical objective is to reduce circulating triglyceride levels to below the threshold associated with significant chylomicronemia, thereby lowering acute pancreatitis risk and improving quality of life.
References
DOI: 10.4158/EP-2018-0157
- Current management to reduce triglyceride levels in FCS patients relies on the adoption of a very-low-fat diet consisting of total fat intake <10 to 15% of daily calories (i.e., <20 to 30 g of fat per day).
- Patients should also meet National Institutes of Health Institute of Medicine dietary intake recommendations for essential fatty acids (i.e., α-linolenic acid and linoleic acid [1 to 1.5 g/day]), and their diet should be appropriately supplemented with fat-soluble vitamins and minerals.
- In addition to significant limitation of dietary fat, patients need to restrict alcohol intake and avoid certain medications that may elevate triglycerides.
- The very-low-fat diet is the only available management for FCS as of the writing of this paper, and patients often report difficulty in implementing and following the required dietary guidelines.
- Hence, the goal of FCS therapy should be to reduce triglyceride levels in patients to below the threshold for significant chylomicronemia (750 to 880 mg/dL) in order to reduce acute pancreatitis risk and improve the quality of life.
View source ↗